A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma

Sponsor
University College, London
Study ID
NCT05074992
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ipilimumab — DRUG
    Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.

Study Details

The NeAT Glio trial will evaluate whether the addition of ipilimumab prior to the current standard treatment of surgery and chemoradiotherapy will improve survival in patients with newly diagnosed glioblastoma.

Key Dates

Start date
Aug 24, 2022
Status verified
May 2024
Primary completion
May 2, 2023
Completion
May 2, 2023

Study Design

Enrollment
1 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ipilimumab
    3mg/kg Ipilimumab IV infusion (day 1) given as a 21 day cycle for 2 cycles.

Primary Outcome Measure

Survival rate at 24 months [ Time Frame: 24 months after diagnostic biopsy ]

Related Studies